¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"double antibody method"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • enzyme labeled antibody
    È¿¼ÒÇ¥ÁöÇ×ü
  • enzyme-antibody conjugate
    È¿¼ÒÇ×üÁ¢ÇÕü
  • fluorescent antibody
    Çü±¤Ç×ü
  • fluorescent antibody technique
    Çü±¤Ç×ü¹ý
  • fluorescent antibody test
    Çü±¤Ç×ü°Ë»ç
  • fluorescent treponemal antibody absorption test
    Çü±¤¸Åµ¶Ç×üÈí¼ö°Ë»ç
  • heat labile antibody
    ¿­¹Î°¨Ç×ü, ¿­ºÒ¾ÈÁ¤Ç×ü
  • hemagglutination inhibition antibody
    ÀûÇ÷±¸ÀÀÁý¾ïÁ¦Ç×ü
  • hemolytic antibody
    ¿ëÇ÷Ç×ü
  • heterocytotropic antibody
    ÀÌÁ¾¼¼Æ÷ģȭÇ×ü
  • heterophil antibody
    ÀÌÁ¾Ä£È­Ç×ü
  • heterophil antibody reaction
    ÀÌÁ¾Ä£È­Ç×ü¹ÝÀÀ
  • heterophil antibody test
    ÀÌÁ¾Ä£È­Ç×ü°Ë»ç
  • homologous antibody
    µ¿Á¾Ç×ü
  • humoral antibody
    ü¾×Ç×ü
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • cytophilic antibody
    (¢¡cytotropic antibody) ¼¼Æ÷ģȭÇ×ü
  • cytotoxic antibody
    ¼¼Æ÷µ¶¼ºÇ×ü
  • cytotropic antibody
    ¼¼Æ÷ģȭÇ×ü
  • diagnostic antibody
    Áø´Ü¿ëÇ×ü
  • divalent antibody
    À̰¡Ç×ü
  • enzyme labeled antibody
    È¿¼ÒÇ¥ÁöÇ×ü
  • fluorescent antibody
    Çü±¤Ç×ü
  • heat labile antibody
    ¿­¹Î°¨Ç×ü
  • hemagglutination inhibition antibody
    ÀûÇ÷±¸ÀÀÁý¾ïÁ¦Ç×ü
  • hemolytic antibody
    ¿ëÇ÷Ç×ü
  • heterocytotropic antibody
    ÀÌÁ¾¼¼Æ÷ģȭÇ×ü
  • heterogenetic antibody
    (¢¡heterophil antibody) ÀÌÁ¾Ä£È­Ç×ü
  • heterophil antibody
    ÀÌÁ¾Ä£È­Ç×ü
  • homocytotropic antibody
    (¢¡cytotropic antibody) ¼¼Æ÷ģȭÇ×ü
  • homologous antibody
    »óµ¿Ç×ü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • acetylcholine receptor antibody assay
    ¾Æ¼¼Æ¿Äݸ°¼ö¿ëü Ç×Ã¼ÃøÁ¤
  • adcc(antibody dependent cell mediated cytotoxicity)
    Ç×üÀÇÁ¸¼¼Æ÷¸Å°³¼¼Æ÷µ¶¼º(ù÷ô÷ëîðíá¬øàØÚË¿á¬øàÔ¸àõ)
  • albumin agglutinating antibody
    ¾ËºÎ¹ÎÀÀÁýÇ×ü(¡­ëêó¢ù÷ô÷).
  • anti-La antibody
    Ç×LaÇ×ü
  • anti-RNP antibody
    Ç× RNPÇ×ü
  • anti-Ro antibody
    Ç× RoÇ×ü
  • anti-SM antibody
    Ç×SMÇ×ü
  • anti-cardiolipin antibody
    Ç×Ä«µð¿À¸®ÇÉÇ×ü
  • anti-idiotype antibody
    Ç×À̵ð¿ÀŸÀÔÇ×ü, Ç×°³º°Æ¯ÀÌÇüÇ×ü
  • anti-sm antibody
    Ç×Sm Ç×ü(ù÷¡­ù÷ô÷)
  • antibody
    Ç×ü(ù÷ô÷)
  • antibody
    Ç×ü(ù÷ô÷)
  • antibody
    Ç×ü
  • antibody absorption
    Ç×üÈíÂø
  • antibody absorption test
    Ç×üÈí¼ö½ÃÇè(ù÷ô÷ýåâ¥ãËúÐ).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • double outlet right ventricle
    ¾ç´ëÇ÷°ü ¿ì½É½Ç±â½Ã.
  • double outlet ventricle
    ¾ç´ëÇ÷°ü µ¿Àϱâ½Ã½É½Ç.
  • double outlet ventricle
    ¾ç´ëÇ÷°ü µ¿Àϱâ½Ã½É½Ç.
  • double outlet ventricle
    ¾ç´ëÇ÷°ü µ¿Àϱâ½Ã½É½Ç.
  • double pain
    ÀÌÁßÅë°¢(ì£ñì÷×ÊÆ).
  • double perforation
    ÀÌÁßõ°ø
  • double placenta
    ÀÌÁߏÝ
  • double quartan (fever)
    Áߺ¹»çÀÏ¿­(ñìÜÜÞÌìíæð).
  • double response
    ÀÌÁß¹ÝÀÀ(¡­Úãëë).
  • double rooted teeth
    º¹±ÙÄ¡(ÜÜÐÆöÍ).
  • double salt
    º¹¿°(ÜÜç¤).
  • double sampling
    ÀÌÂ÷Ç¥º»ÃßÃâ(Ëö̤̰ËÓ̧̧), ÀÌÁßÇ¥º»(¹ý).
  • double sensation
    ÀÌÁß°¨°¢(¡­ÊïÊÆ).
  • double sided
    ¾çÃø¼º(å»ö°àõ).
  • double simultaneous stimulation
    ÀÌÁß µ¿½ÃÀÚ±Ø
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • Dean and Webb method
    µò°ú¿þºê ¹ý(Ûö)
  • deletion method
    °á¼Õ¹ý(ÌÀáßÛö)
  • differential method
    °¨º°¹ý(ÊüܬÛö)
  • DNAase protection method
    DNAase º¸È£¹ý(ÜÁûÞÛö)
  • end-point method
    Á¾¸»Á¡¹ý(ðûØÇïÇÛö)
  • Fiske-SubbaRow method
    ÇǽºÄÉ-»ç¹Ù·Î¿ì ¹ý(Ûö)
  • flow method
    È긲¹ý(Ûö)
  • flux ratio method
    Çöô½º ºñÀ²¹ý(Ýï×ËÛö)
  • Folch method
    ÆúÃ÷¹ý(Ûö)
  • Folin method
    Æú¸°¹ý(Ûö)
  • Folin-Wu method
    Æú¸°-¿ì¹ý(Ûö)
  • gaseous exposure method
    °³½º ³ëÃâ¹ý(ÖÚõóÛö)
  • Gilbert-Maxam method
    ±æ¹öÆ®-¸Æ»ï¹ý(Ûö)
  • gradient-flow method
    ±¸¹è(ÎþÛÕ)-È帧¹ý(Ûö)
  • heavy atom method
    Áß¿øÀÚ¹ý(ñìê«í­Ûö)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
CPM central pontine myelinosis; chlorpheniramine maleate; continuous passive motion; critical path metho...
CPRAM controlled partial rebreathing anesthesia method
DBCL dilute blood clot lysis [method]
DEALE declining exponential approximation of life expectancy [method]
3DFEM three-dimensional finite element method
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
DBPCFC Double-blind placebo-controlled food challenge
DCRV Double-chambered right ventricle
DQF-COSY Double-quantum filtered correlation spectroscopy
DS Double-strand
DSB Double-strand DNA break
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • double loop strangulation
    ÀÌÁß °¨µ·
  • double lumen catheter
    ÀÌÁß °ü Ä«Å×Å׸£
  • double nasal blindness
    ¾ç ºñÃø ¹Ý¸Í
  • double orientation
    ÀÌÁß ÁöÇâ
  • double outlet left ventricle
    ¾ç ´ëÇ÷°ü ÁÂ½É½Ç ±â½Ã
  • double pain
    ÀÌÁß Åë°¢
  • double personality
    ÀÌÁß ÀΰÝ
    ¾î¶² °³Ã¼°¡ µÎ ÁöÀÇ »ýȰÀ» ±³´ë·Î ¹Ýº¹ÇÏ´Â ÀǽÄÀÇ Àå¾Ö.
  • double quartan fever
    Áߺ¹ »çÀÏ ¿­
  • double rooted teeth
    º¹±ÙÄ¡
  • double sampling
    ÀÌÂ÷ Ç¥º» ÃßÃâ
  • double sensation
    ÀÌÁß °¨°¢
  • double simultaneous stimulation
    ÀÌÁß µ¿½Ã ÀÚ±Ø
  • double space arthrogram
    ÀÌÁß°­ °üÀý Á¶¿µ »çÁø
  • double staining
    ÀÌÁß ¿°»ö¹ý
  • double strand DNA
    ÀÌÁß¼â DNA
    ´ëºÎºÐÀÇ bacterio
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
antiphospholipid antibody syndrome <syndrome> An immune disorder characterised by the presence of abnormal antibodies in the blood associated with certain medical conditions including abnormal blood clotting, migraine headaches, premature miscarriage, and low blood platelet counts (thrombocytopenia).
(12 Dec 1998)
antithyroglobulin antibody <endocrinology, immunology> A serologic blood test which measures the antithyroglobulin antibodies in the blood. Thyroglobulin is a protein found in thyroid tissue. It is the source of thyroid hormones in the body.
The presence of antibodies to this protein can result in decreased thyroid gland function. A negative assay is considered normal.
Conditions where the assay may be positive include: lupus, rheumatoid arthritis, Hashimoto's thyroiditis, thyrotoxicosis, hypothyroidism, thyroid cancer, myxoedema, Sjogren's syndrome and autoimmune haemolytic anaemia.
(13 Jan 1998)
avidity antibody The sum total of the functional binding strength between a polyvariant and its antibody. The total binding strength represents the sum strength of all the affinity bonds.
(05 Mar 2000)
binding sites, antibody Local surface sites on antibodies which react with antigen determinant sites on antigens. They are formed from parts of the variable regions of the fab fragment of the immunoglobulin.
(12 Dec 1998)
bivalent antibody Antibody that causes a visible reaction with specific antigen as in agglutination, precipitation, and so on; so-called because according to the "lattice theory" aggregation occurs when the antibody molecule has two or more binding sites that can crosslink one antigen particle to another; probably a characteristic of the class of immunoglobulin.
(05 Mar 2000)
blocking antibody An antibody used in a reaction to prevent some other reaction taking place, for example one antibody competing with another for a cell surface receptor.
See: desensitisation.
(18 Nov 1997)
reaginic antibody <immunology> A type of antibody which is able to attach itself to the surfaces of cells without needing specific combining sites. A homocytotropic antibody will only bind to cells which are from the same species as itself.
(09 Oct 1997)
maternal antibody Any antibody transferred from a mammalian mother transplacentally into the foetus. See under immunoglobulin for details of the classes of Ig that are transferred to the foetus.
(18 Nov 1997)
catalytic antibody <chemistry> Antibody raised against a transition state analogue (e.g. A phosphate analogue of a carboxylic acid ester transition state) that can then catalyse the analogous chemical reaction, though not as effectively as a true enzyme.
(16 Mar 1998)
Vi antibody A form of antibody that agglutinates highly virulent strains of Salmonella typhi, i.e., cells with Vi antigen; such bacteria are not agglutinable with O antiserum until the Vi antigen is destroyed.
See: Vi antigen.
(05 Mar 2000)
cell-bound antibody A term used for antibody on the surface of cells that may be bound either through antigen combining sites or other sites such as the Fc region.
(05 Mar 2000)
CF antibody Antibody that combines with and sensitises antigen leading to the activation of complement, which may result in cell lysis.
Synonym: CF antibody, sensitizing substance.
(05 Mar 2000)
chimeric antibody <immunology> An antibody that contains polypeptides from different species.
(05 Jan 1998)
chimeric/humanised antibody <immunology> Genetically engineered combination of a human and mouse antibody. Because a monoclonal antibody is always made with mice cells, it causes an immune response when injected into humans.
By replacing the constant regions of a mouse antibody with those of a human antibody, an antibody that binds to an antigen like the original monoclonal antibody, but which is recognised by the human immune system like a human protein, can be manufactured. Alternatively, only those amino acids directly involved in antigen binding are transferred from the mouse antibody into the framework of the human antibody, with a similar result.
(05 Jan 1998)
microsomal antibody This special serologic test is used to measure thyroid anti-microsomal antibody in the bloodstream. This test can be performed from a simple venipuncture specimen. The anti-microsomal antibody or microsomal antibody test is used to diagnose conditions such as Hashimoto's thyroiditis and other autoimmune disorders.
(27 Sep 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
ÅëÇÕ°Ë»ö ¿Ï·á